• Oscar Health recently presented at the 47th Annual Raymond James Institutional Investor Conference in Orlando, where its CFO reiterated the 2026 outlook and addressed policy and capital concerns.
• Management also highlighted stronger-than-expected enrollment of 3.4 million members and extensive reinsurance support, underscoring how scale and risk-sharing underpin the business model.
• Next, we’ll explore how this reaffirmed outlook and higher enrollment may influence Oscar Health’s investment narrative and risk-reward profile.

Uncover the next big thing with 32 elite penny stocks that balance risk and reward.

Oscar Health Investment Narrative Recap

To own Oscar Health, you need to believe its tech-focused model can convert strong ACA exchange enrollment into sustainable profitability while managing regulatory and capital pressures. The Raymond James conference reaffirmed 2026 guidance and highlighted higher enrollment, which supports the near term earnings-from-operations goal, but does not remove the key risk around policy shifts and exchange market shrinkage.

Among recent announcements, the new US$475.0 million revolving credit facility stands out, as it sits alongside the expanded reinsurance support management emphasized at the conference. Together, these moves illustrate how Oscar is trying to balance growth in membership-driven revenue with access to liquidity and risk sharing, both central to the current catalyst of moving from persistent losses toward the 2026 EFO target.

Yet behind the stronger enrollment and capital cushions, investors still need to watch how exposed Oscar remains to potential changes in ACA subsidies and...

Oscar Health's narrative projects $12.4 billion in revenue and $245.4 million in earnings by 2028. This requires 4.9% yearly revenue growth and a $406.6 million increase in earnings from -$161.2 million today.

Uncover how Oscar Health's forecasts yield a $15.78 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already penciling in roughly US$13.8 billion of 2028 revenue and US$574.6 million of earnings, assuming regulatory risks like subsidy changes do not bite too hard.

Explore 20 other fair value estimates on Oscar Health - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Oscar Health research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Oscar Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oscar Health's overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 49 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.